

# The Innovative Medicines Initiative Europe's partnership for Health

**ISC GDPR seminar: The Impact of the General Data Protection Regulation  
on the use of personal data for science, in particular health science**

Brussels • 27.04.2017

# IMI IP policy supports open innovation & data access

Background identification

Start

Implementation of the IMI action

End

Results

Access rights (implementation / Research Use)

Open Access to scientific publications

Access rights (implementation / RU of results)

**Sideground**

Generated during the IMI action but **outside its objectives** and not needed for action implementation or research use


# Preliminary answers to data challenges

At IMI level

- Harmonised approach for **patient consent form**
  - Across EU funded programmes?
- Harmonised approach for **data integration** from multiple sources, multiple types etc.
  - Data centre / Joint repository
- Ensure **sustainability of valuable data-rich assets** developed during IMI projects
  - Research Infrastructures?
- Educate IMI community on **use/re-use** of the data sets
  - Guidelines?

# New Drugs for Bad Bugs (ND4BB)

## Cross-project communication & collaboration



## ND4BB Information Centre

All data generated is submitted and made accessible to all partners



Drug discovery

Drug development (Gram-positives)

Drug development (Gram-negatives)

Economics & stewardship

# The IMI Ebola+ programme

## FILODIAG

GNA Biosolutions

**Ultra-fast diagnostics based on laser-heated nanoparticles**

## EbolaMoDRAD

Public Health Institute Sweden

**Portfolio of rapid diagnostic tools**

## EBOVAC 1

LSHTM, Janssen

**Phase 1 & 3 trials Janssen prime-boost vaccine**

## EBOVAC 2

Inserm, Janssen

**Phase 2 trials Janssen prime-boost vaccine**

## EBODAC

LSHTM, Janssen

**Deployment & compliance**

## EBOMAN

Vibalogics, Janssen

**Manufacturing challenges**

## Mofina

Public Health England, Altona

**Mobile pan-filovirus nucleic acid test**

## VSV-EBOVAC

Sclavo Vacc. Assoc

**In-depth immunogenicity VSV-ZEBOV**

- Joint Information Repository
- Joint Scientific Advisory Board
- Joint Ethics Board

# Data Challenges

- Possible discrepancies at national level
  - Limits to **pseudonymisation** of personal data?
  - **Data interfaces** (research / clinic) at scale and internationally
  - **Data standards**
- Extend to which the IMI concept of **Research Use** is part of the exemption (art.9. i-j)
  - Area of public health
  - Scientific or historical research purposes
- Cross-border collaborations
  - **International transfer** of data

# Thank you

Magali Pointot • Advisor to the Executive Director  
[magali.pointot@imi.europa.eu](mailto:magali.pointot@imi.europa.eu)

[www.imi.europa.eu](http://www.imi.europa.eu)

 @IMI\_JU  [bit.ly/LinkedInIMI](https://bit.ly/LinkedInIMI)